GOETTINGEN, Germany/Bohemia & NEW YORK–Dr. Yujing Yang recently assumed the position of Director of Purification Technologies, North America. He brings broad experience in all areas of biopharmaceutical downstream processing and in-depth knowledge of biotech-related technologies, such as Xflow filtration and membrane chromatography, to Sartorius Stedim Biotech (Paris:DIM). In his current position, Dr. Yang reports to Dr. Uwe Gottschalk, Vice President of Marketing, Purification Technologies. Dr. Yang obtained both his Bachelor’s and Master’s degrees in Engineering from Tsinghua University in Beijing, China, and earned his Ph.D. in Environmental Biology at the University of Massachusetts in Boston, where he conducted research on cloning and won a number of awards.

Before joining Sartorius Stedim Biotech, Dr. Yujing Yang was Industrial Commercial Leader for Life Sciences in Greater China at GE Healthcare, where he was responsible for marketing, sales and support teams. Prior to assuming this position, he was Technical Marketing Director for Asia, and held various positions in business development, product management, application and technical support. Dr. Yang, who has been working in the field of biopurification for twelve years, was employed in various management and research positions at Pall Corporation, the U.S. National Research Council and the Boston Biomedical Research Institute. He also taught as an Assistant Professor for three years at Tsinghua University and has four bioprocessing patents to his name.

Current image file:

Dr. Yujing Yang, Director of Purification Technologies, North America, at Sartorius Stedim Biotech.

https://www.sartorius-stedim.com/media/content/press/support/Yujing_Yang.jpg

A profile of Sartorius Stedim Biotech

Sartorius Stedim Biotech is a leading provider of cutting-edge equipment and services for the development, quality assurance and production processes of the biopharmaceutical industry. Its integrated solutions covering fermentation, filtration, purification, fluid management and lab technologies are supporting the biopharmaceutical industry around the world to develop and produce drugs safely, timely and economically. For next-generation processes, Sartorius Stedim Biotech focuses on single-use technologies and value-added services to meet the rapidly changing technology requirements of the industry it serves. Strongly rooted in the scientific community and closely allied with customers and technology partners, the company is dedicated to its philosophy of “turning science into solutions” on a daily basis.

Headquartered in Aubagne, France, Sartorius Stedim Biotech is listed on the Eurolist of Euronext Paris. With its own manufacturing and R&D sites in Europe, North America and Asia and a global network of sales companies, Sartorius Stedim Biotech enjoys a worldwide presence. Its key manufacturing and R&D site is in Germany. The company employs over 2,300 people, and in 2008 generated sales revenue of 368.0 million euros.